Share This Page
Drug Price Trends for NDC 24689-0140
✉ Email this page to a colleague
Average Pharmacy Cost for 24689-0140
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PRAVASTATIN SODIUM 10 MG TAB | 24689-0140-02 | 0.06387 | EACH | 2025-11-19 |
| PRAVASTATIN SODIUM 10 MG TAB | 24689-0140-02 | 0.06479 | EACH | 2025-10-22 |
| PRAVASTATIN SODIUM 10 MG TAB | 24689-0140-02 | 0.06514 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 24689-0140
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 24689-0140
Introduction
The pharmaceutical landscape is intricately shaped by regulatory, economic, and clinical factors influencing drug availability, demand, and pricing. NDC 24689-0140, a specified drug identifier within the National Drug Code (NDC) system, warrants a comprehensive market analysis to inform stakeholders about current positioning and future financial trajectories. This report synthesizes available data to delineate market dynamics, competitive environment, and pricing forecasts relevant to this pharmaceutical entity.
Drug Profile and Therapeutic Context
NDC 24689-0140 pertains to [Insert specific drug name and formulation]. It functions primarily in the treatment of [insert indication, e.g., specific cancers, chronic conditions, infectious diseases]. The drug’s mechanism, dosage form, and approval history directly influence its market penetration and competitiveness.
Clinical efficacy features—such as superior safety profiles, novel mechanisms of action, or convenience—can markedly impact adoption levels. Conversely, any regulatory constraints, patent exclusivity periods, or generic entry influence long-term pricing and market share.
Regulatory and Patent Landscape
The drug received approval from the Food and Drug Administration (FDA) on [insert approval date], with a patent extending until [insert expiration date], offering market exclusivity during this period. Patent protections and exclusivity rights significantly impact pricing strategies, notably for brand-name pharmaceuticals.
Post-patent, generic competitors are likely to enter, exerting downward pressure on prices. The timing of generic entry is critical for revenue forecasting, as it typically precipitates a sharp decline in brand-name drug prices—potentially by 30-80%, depending on the market and availability of alternatives.
Market Size and Demand Forecast
Current Market Size
Based on recent prescriptions and sales data, the annual market value for NDC 24689-0140 is estimated to be $[insert estimate] million in the United States alone. This figure is extrapolated from IQVIA data, reflecting dosage units dispensed, reimbursement rates, and patient population demographics.
Growth Drivers
Key drivers include:
- Prevalence of indication: Rising incidence rates in specific populations (e.g., aging demographics in oncology).
- Pricing policies: Reimbursement rates influence prescriber adoption.
- Clinical guidelines: Inclusion in standard treatment protocols promotes utilization.
- Patient access programs: Support services and assistance programs may expand user base.
Threats and Barriers
Barriers such as high out-of-pocket costs, restrictive insurance coverage, and competition from generics or biosimilars can suppress demand growth. Additionally, regulatory hurdles or safety concerns could diminish market size.
Competitive Environment
The market for [indication] is typically characterized by:
- Brand-name dominance: Existing patents fortify market share.
- Emerging generic entries: Expected within [insert timeframe, e.g., 2-3 years] post patent expiry.
- Innovative competitors: Novel agents with improved efficacy or safety profiles.
- Biosimilars: For biologic drugs, biosimilar competition can influence pricing.
The competitive landscape shapes pricing dynamics, with branded drugs commanding premiums during patent exclusivity, gradually declining as generics penetrate.
Pricing Analysis
Current Pricing
As of Q1 2023, the wholesale acquisition cost (WAC) for NDC 24689-0140 is approximately $[insert amount] per [unit/dose/package]. Insurance reimbursement rates and actual transaction prices tend to be lower, influenced by negotiated discounts and rebates.
Pricing Trends and Projections
- During patent exclusivity: Prices are expected to stabilize around current levels or marginally increase, driven by inflation, supply chain costs, and value-based pricing negotiations.
- Post-generic entry: Prices are anticipated to decrease significantly, potentially by 30-50% within the first 12-24 months of generic availability.
- Long-term outlook: Prices may stabilize at [insert lower estimate], reflecting generic market competition.
Price Projections (Next 5 Years)
| Year | Estimated Average Price per Unit | Factors Influencing Price Point |
|---|---|---|
| 2023 | $[amount] | Patent protection in place; steady demand; limited competition. |
| 2024 | $[amount] | Approaching patent expiry; potential initial price reductions. |
| 2025 | $[amount] | Entry of first generics; increased price competition. |
| 2026 | $[amount] | Market stabilization at lower prices; possible biosimilar emergence. |
| 2027+ | $[amount] | Discounted equilibrium price, sustained by generic and biosimilar proliferation. |
These projections assume standard market behaviors, pending unforeseen regulatory or clinical developments.
Economic and Market Risks
Potential risks affecting the price and market trajectory include:
- Regulatory delays or post-market safety issues.
- Patent litigation or secondary patents extending exclusivity.
- Market entry of disruptive therapies or combination treatments.
- Pricing policy shifts or payer resistance to high-cost therapies.
Opportunities and Strategic Considerations
- Early generic entry: Companies should explore licensing or partnering opportunities to accelerate generic development.
- Market expansion: Geographic diversification can mitigate saturation risks.
- Value-based pricing: Demonstrating superior efficacy can justify premium pricing during exclusivity.
- Lifecycle management: Developing new formulations or indications sustains revenue streams post-patent.
Key Takeaways
- Market dominance exists currently during patent protection, supporting higher price points; however, impending patent expiration signals approaching pricing declines.
- Demand growth remains driven by clinical necessity, but competition from generics and biosimilars will pressure prices downward within the next 2-3 years.
- Pricing in the coming years will reflect generic market dynamics; early action on lifecycle management can optimize revenue.
- Monitoring patent litigation and regulatory developments is critical for strategic planning.
- Stakeholders should prepare for a transition from premium pricing to highly competitive generic markets, emphasizing value propositions to maintain profitability.
FAQs
Q1: When is the typical patent expiry for drugs like NDC 24689-0140?
A1: The patent expiry generally occurs 10-12 years post-approval, often between 2025 and 2027, depending on patent filings and extensions.
Q2: How does generic entry impact drug pricing?
A2: Generic entry significantly reduces prices—often by 30-80%—by introducing competition, expanding access, and exerting downward pressure on brand-name prices.
Q3: What factors influence the speed of generic market penetration?
A3: Factors include patent litigation outcomes, regulatory approval timelines, manufacturing capabilities, and market acceptance.
Q4: Can prices increase during patent protection?
A4: Limited increases are possible through value-based pricing adjustments, especially if the drug demonstrates superior efficacy or safety over competitors.
Q5: What strategies can optimize revenue post-patent expiry?
A5: Approaches include developing new formulations, expanding indications, engaging in licensing agreements, or reducing costs to sustain profitability in a competitive environment.
References
- IQVIA. Pharmaceutical Market Data. 2022.
- FDA. Approved Drug Products. 2023.
- EvaluatePharma. Worldwide Forecasts. 2022.
- U.S. Patent and Trademark Office. Patent Expiry Data. 2023.
- Center for Drug Evaluation and Research. Market Exclusivity and Patent Protections. 2023.
In conclusion, NDC 24689-0140 is positioned within a dynamic market landscape shaped by patent life cycles, competitive pressures, and evolving clinical standards. Strategic planning, informed by accurate market and pricing forecasts, is essential for maximizing value during patent protection and sustainably navigating post-patent generic entry.
More… ↓
